Verastem’s (VSTM) “Buy” Rating Reiterated at BTIG Research
BTIG Research reiterated their buy rating on shares of Verastem (NASDAQ:VSTM – Free Report) in a research report sent to investors on Friday,Benzinga reports. BTIG Research currently has a $18.00 price target on the biopharmaceutical company’s stock. Other analysts also recently issued reports about the stock. Weiss Ratings upgraded shares of Verastem from a “sell […]
14 Sep 06:06 · The Markets Daily